Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare Biotechnology
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium to Host Conference Call to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update

GlobeNewswire August 4, 2016

Collegium Gets European Patent Allowance Covering Its Xtampza

Benzinga.com  August 1, 2016

Collegium Receives European Patent Allowance Covering Xtampza® ER

GlobeNewswire August 1, 2016

Collegium to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

GlobeNewswire July 6, 2016

Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year

GlobeNewswire June 27, 2016

Collegium Announces Positive Topline Results for Hydrocodone DETERx® Clinical Study

GlobeNewswire June 22, 2016

Collegium Announces Commercial Launch of Xtampza® ER

GlobeNewswire June 20, 2016

Collegium Announces Election of John A. Fallon, M.D. to Board of Directors

GlobeNewswire June 13, 2016

Collegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids

GlobeNewswire June 2, 2016

Collegium to Present at Jefferies and William Blair Conferences

GlobeNewswire June 2, 2016